Core Viewpoint - Wangshan Wangshui-B (02630) has successfully listed, with a share price set at HKD 33.37, raising approximately HKD 527 million from the issuance of 17.5978 million shares [1] Company Overview - Established in 2013, Wangshan Wangshui is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing small molecule drugs in its strategic therapeutic areas, specifically neuropsychiatric and reproductive health [1] - The company has developed two core products: LV232, a dual-target 5-HTT/5-HT3 receptor modulator for the treatment of major depressive disorder, and TPN171, a PDE5 inhibitor for erectile dysfunction [1] - Additionally, the company has four candidate drugs in clinical stages and three candidate drugs in preclinical stages [1] Market Performance - As of the latest update, the stock price surged by 184.69% to HKD 95, with a trading volume of HKD 274 million [1]
港股异动 | 旺山旺水-B(02630)首挂上市 早盘高开184.69% 公司专注于神经精神、生殖健康领域小分子药物